Nobutaka Hanagata

Summary

Affiliation: National Institute for Materials Science
Country: Japan

Publications

  1. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine. 2012;7:2181-95 pubmed publisher
    ..Because CpG ODNs interact with TLR9 and activate both the innate and the adaptive immune system, the application of CpG ODNs for the treatment of cancers, infectious diseases, and allergies holds great promise. ..
  2. Hanagata N. IFITM5 mutations and osteogenesis imperfecta. J Bone Miner Metab. 2016;34:123-31 pubmed publisher
    ..In this review, the current state of knowledge of OI pathological mechanisms due to IFITM5 mutations will be reviewed. ..
  3. Chen S, Du X, Jia L, Chang H, Ikoma T, Hanagata N. Synthesis and osteo-compatibility of novel reduced graphene oxide-aminosilica hybrid nanosheets. Mater Sci Eng C Mater Biol Appl. 2016;61:251-6 pubmed publisher
    ..Thus, the resultant hybrids nanosheets had a potential application in the bone regeneration. ..
  4. Chen M, Jenh Y, Wu S, Chen Y, Hanagata N, Lin F. Non-invasive Photodynamic Therapy in Brain Cancer by Use of Tb3+-Doped LaF3 Nanoparticles in Combination with Photosensitizer Through X-ray Irradiation: A Proof-of-Concept Study. Nanoscale Res Lett. 2017;12:62 pubmed publisher
    ..The study has demonstrated a proof of concept as a non-invasive way to treat brain cancer in the future. ..
  5. Meng W, Yamazaki T, Nishida Y, Hanagata N. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotechnol. 2011;11:88 pubmed publisher
    ..We propose these CpG ODNs consisting of only a PD backbone as a novel class of CpG ODN. ..
  6. Hanagata N, Li X, Morita H, Takemura T, Li J, Minowa T. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab. 2011;29:279-90 pubmed publisher
    ..Overall, the effect of Ifitm5 deficiency on bone formation was less than we expected. We hypothesize that this may have resulted from a compensatory mechanism in Ifitm5-deficient mice. ..
  7. Hanagata N, Li X. Osteoblast-enriched membrane protein IFITM5 regulates the association of CD9 with an FKBP11-CD81-FPRP complex and stimulates expression of interferon-induced genes. Biochem Biophys Res Commun. 2011;409:378-84 pubmed publisher
    ..Induction of these genes likely resulted from dissociation of CD9 from the FKBP11-CD81-[FPRP/CD9] complex. Cumulatively, these results suggest that IFITM5 is involved not only in bone formation, but also in immune system activity. ..